A study published in The American Journal of Clinical Nutrition compared the effects of orlistat and an experimental high-protein/lower-carbohydrate diet with a control diet in Asian patients with obesity and Metabolic-associated fatty liver disease (MAFLD). Results showed that all three groups demonstrated improvement in liver steatosis at week 24. The orlistat group and the experimental diet group had significantly greater reductions in liver fat content (LFC) compared to the control group. The relative reduction in LFC was 30.2% in the experimental diet group, which was significantly higher than the 12.2% observed in the control group. Authors suggest that these interventions could be useful in the management of MAFLD, particularly in populations where compliance with lifestyle interventions may be challenging. However, further research is needed to determine the long-term efficacy and safety of these interventions.
Today: December 6, 2023